{"entity":{"id":"nct06733441","kind":"trial","name":"A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma","aka":[],"tldr":"A phase 1 trial of Zeprumetostat run by Treeline Biosciences, Inc., active and no longer recruiting.","summary":"A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma is a phase 1 interventional study registered as NCT06733441 by Treeline Biosciences, Inc., with 50 participants planned, started 2024-12-16. Conditions recorded: Lymphoma. Interventions recorded: TLN-254 and TLN-254.","status":"active","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06733441","url":"https://clinicaltrials.gov/study/NCT06733441"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["zeprumetostat"],"companies":["treeline-biosciences","hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06733441","phase":"1","setting":"Phase 1b, Randomized, Dose Optimization Study to Assess the Anti-Tumor Activity, Safety, and Pharmacokinetics of TLN-254 in Patients With Relapsed or Refractory T-cell Lymphoma","sponsor":"Treeline Biosciences, Inc.","enrolled":50,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06733441/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"zeprumetostat","kind":"drug","name":"Zeprumetostat","route":"/drugs/zeprumetostat/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"},{"id":"treeline-biosciences","kind":"company","name":"Treeline Biosciences","route":"/companies/treeline-biosciences/"}]}}